190 related articles for article (PubMed ID: 38074921)
1. Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review.
Matsumoto T; Sakurai Y; Tashima N; Matoba T; Kaneko A; Fujiki T; Kusakabe Y; Nakayama E; Tanaka A; Tashima M; Yamamoto N; Aihara K
Respirol Case Rep; 2024 Jan; 12(1):e01266. PubMed ID: 38074921
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tezepelumab against uncontrolled severe non-type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab.
Kai Y; Suzuki K; Kataoka R; Sato I; Tamaki S; Muro S
Respirol Case Rep; 2024 Mar; 12(3):e01311. PubMed ID: 38420113
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
[TBL] [Abstract][Full Text] [Related]
4. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis - A Real-life Experience.
Abuzakouk M; Ghorab OKHA; Wahla AS; Zoumot Z; Nasir M; Grandon D; Uzbeck MH; Salvo F; Shafiq I
Open Respir Med J; 2020; 14():99-106. PubMed ID: 33717370
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation.
L Ramos C; Namazy J
Immunol Allergy Clin North Am; 2023 Feb; 43(1):187-197. PubMed ID: 36411004
[TBL] [Abstract][Full Text] [Related]
7. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
8. Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis.
Suhling H; Hinze CA; Welte T; Werfel T; Traidl S
Respiration; 2023; 102(12):1016-1019. PubMed ID: 38008067
[TBL] [Abstract][Full Text] [Related]
9. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
10. Safety of Biologics for Atopic Diseases During Pregnancy.
Shakuntulla F; Chiarella SE
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3149-3155. PubMed ID: 35987486
[TBL] [Abstract][Full Text] [Related]
11. Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases.
Pitlick MM; Pongdee T
World Allergy Organ J; 2022 Nov; 15(11):100707. PubMed ID: 36267353
[TBL] [Abstract][Full Text] [Related]
12. [Biologics in severe childhood asthma].
Amat F
Rev Mal Respir; 2023 Oct; 40(8):675-683. PubMed ID: 37749027
[TBL] [Abstract][Full Text] [Related]
13. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
14. A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
Davison J; Doe S
Respir Med Case Rep; 2021; 34():101557. PubMed ID: 34877251
[TBL] [Abstract][Full Text] [Related]
15. The evolving landscape of immunotherapy for the treatment of allergic conditions.
Pandya A; Adah E; Jones B; Chevalier R
Clin Transl Sci; 2023 Aug; 16(8):1294-1308. PubMed ID: 37170653
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps.
Koski RR; Hill L; Taavola K
J Pharm Technol; 2022 Oct; 38(5):289-296. PubMed ID: 36046351
[No Abstract] [Full Text] [Related]
18. Biologics for oral corticosteroid-dependent asthma.
Yılmaz İ
Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
[No Abstract] [Full Text] [Related]
19. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.
Numata T; Araya J; Miyagawa H; Okuda K; Fujita Y; Utsumi H; Takekoshi D; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Kuwano K
J Asthma Allergy; 2021; 14():609-618. PubMed ID: 34113131
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
Ragnoli B; Morjaria J; Pignatti P; Montuschi P; Barbieri M; Mondini L; Ruggero L; Trotta L; Malerba M
Ther Adv Chronic Dis; 2022; 13():20406223221097327. PubMed ID: 35655942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
